Faes Farma (FAE) CMD 2025 summary

Strategic vision and leadership

• New CEO appointed in September, bringing over 20 years of global pharma experience and driving a renewed culture, organization, and ambition.

• Transition to a non-executive chairman and separation of powers completed, supporting transformation.

• Global Executive Team restructured, blending internal talent and key external hires, including a new Chief Scientific Officer.

• Faes Farma has evolved from a national to a global company, consolidating its presence in new markets, especially LATAM.

• The workforce is diverse and global, with 1,775 employees across 130+ countries and a balanced gender split.

Financial guidance and growth targets

• Ambition to double sales and nearly double EBITDA by 2030, targeting €1 billion in revenue and €815–845M in revenues with €190–200M in EBITDA, with a CAGR of 11–12% and 10–11% respectively (including M&A).

• Organic growth expected at 8–10% in 2025, with EBITDA growth of 3–5%, absorbing loss of exclusivity impacts.

• Temporary EBITDA dip in 2025 (–6% to –9%) due to Derio plant transition, with recovery expected post-2026.

• CAPEX to decrease significantly after 2025, focusing on maintenance and targeted updates.

• Commitment to maintain a payout ratio around 50%, with continued cash dividends planned for 2025.

Strategic pillars and business development

• Four strategic pillars: accelerate growth, lead through science, achieve commercial/operational excellence, and maximize stakeholder impact.

• Growth driven by pharma (90% of revenue), animal nutrition, innovation, and targeted M&A.

• M&A strategy focuses on acquiring assets that add innovative products, new therapeutic areas, or geographic reach, with strict financial criteria and a target to add ~€170M in sales by 2030.

• Recent acquisition of EDOL opens new opportunities in ophthalmology and strengthens position in Portugal, doubling sales and EBITDA in the country.

• Animal nutrition business aims to more than double revenues by 2027–2028, expanding into poultry and aquaculture, leveraging new ISF plant and vertical integration.